-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $2

Benzinga·11/05/2026 19:00:43
Listen to the news
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1.25 to $2.